Haworth S G
Department of Vascular Biology, Institute of Child Health, University College London, London, WC1N 1EH, UK.
Vascul Pharmacol. 2006 Nov;45(5):317-25. doi: 10.1016/j.vph.2006.08.006. Epub 2006 Aug 18.
Pulmonary hypertension represents a significant disease burden in both the developed and developing worlds. Certain forms of pulmonary hypertension are more common in some countries than others but people of all races, all ages and both sexes are affected. Treatment options are limited and expensive. The development of new therapies will be determined by improved understanding of endothelial cell biology.
肺动脉高压在发达国家和发展中国家都构成了重大的疾病负担。某些形式的肺动脉高压在一些国家比其他国家更为常见,但所有种族、所有年龄和性别的人都会受到影响。治疗选择有限且昂贵。新疗法的开发将取决于对内皮细胞生物学的进一步了解。